Bristol-Myers Squibb said it will buy diabetes drug maker Amylin in a $7 billion deal that will intensify the competition to treat the growing number of people afflicted with the disease.
WSJ.com: What's News US, Wall Street Journal
Fri, 06/29/2012 - 9:39pm
Bristol-Myers Squibb said it will buy diabetes drug maker Amylin in a $7 billion deal that will intensify the competition to treat the growing number of people afflicted with the disease.